Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Overview
• Challenging Times for the Drug Industry
• How Industry Can Meet the Challenge
  • Blockbuster Model Versus Personalized Medicine Model
  • Back to the Basics: Genes
• Mining the Genome for Pharmacogenomic Information
  • The Human Genome Project.
  • The HapMap Project
• Key Commercial Activity in Haplotype Testing
  • Affymetrix
  • Illumina
  • Applied Biosystems
  • Perlegen
  • Clinical Data
  • Celera Genomics
• Commercial Next-Generation Sequencing Systems
  • Roche (454 Life Sciences)' s Platform
  • Illumina (Solexa)' s Genome Analyzer
  • Applied Biosystems' SOLiD Sequencer
  • Helicos' s Helioscope
• Next-Next-Generation Sequencing Systems - the Future?
• NGS-Enabled Innovative Collaborations
  • X Prize Foundation
  • The 1000 Genomes Project
  • The International Cancer Genome Organization
  • The National Human Genome Research Institute
• Outlook
  • Gaining Improvements in Sequencing Methodology
  • Enhancing Drug Discovery Applications
  • Strengthening Biological Knowledge

Tables

• 1. Blockbuster Model Versus Personalized Medicine Model for the Drug Industry
• 2. Personalized Medicine Offers Key Opportunities to the Drug Industry
• 3. Key Challenges of Personalized Medicine for the Drug Industry
• 4. Properties of Select Commercial Next-Generation Sequencing Analyzers
• 5. Select Emerging Next-Generation Sequencing Technology Companies
• 6. NHGRI-Funded Next-Generation Sequencing Projects Announced in August 2008

Figures

• 1. FDA Approval of NMEs Compared with R&D Spending
• 2. Success Rates as Compounds Advance Through Stages of Development
• 3. Next-Generation Sequencing Workfl ows for Commercial Systems